Medios

Medios Rule of 40

The Rule of 40 of Medios (ILM1.DE) as of Nov 9, 2026 is 12.40 %. In the previous year, Rule of 40 was 7.19 % — a change of 72.37% (higher).

Rule of 40

12.40 %

YoY

72.37%

Last updated:

Rule of 40 of Medios is 2025 12.40 % . Rule of 40 of Medios was 2024 7.19 % . It decreases by 72.37% higher compared to the previous year.

The Medios Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
31.51 EUR
Jan 1, 2019
60.43 EUR
Jan 1, 2020
22.76 EUR
Jan 1, 2021
117.77 EUR
Jan 1, 2022
20.46 EUR
Jan 1, 2023
12.56 EUR
Jan 1, 2024
7.19 EUR
Jan 1, 2025
12.40 EUR
The Medios Rule of 40 history
YEARRule of 40YoY
12.40 %+72.37%
7.19 %-42.72%
12.56 %-38.65%
20.46 %-82.62%
117.77 %+417.53%
22.76 %-62.34%
60.43 %+91.78%
31.51 %-66.15%
93.08 %-100.00%
98.87 M %-83,632.81%
-118,354.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medios Stock analysis

What does Medios do? Medios AG is a leading company in the supply of high-quality specialty preparations to patients. The company was founded in Berlin in 2004 and has been listed on the Frankfurt Stock Exchange since 2018. Medios AG quickly achieved a strong position in the German healthcare market and currently employs approximately 300 employees at multiple locations in Germany. The business model of Medios AG is based on the production and distribution of high-quality specialty preparations. These are developed and produced in close collaboration with customers such as hospitals and outpatient clinics. Medios AG's products are typically used to treat rare and chronic diseases, such as immunological diseases, cancer, and metabolic disorders. Medios AG offers a wide range of products and services. The company is divided into three areas. The first area is Medios AG's core business, the distribution of specialty preparations. This area includes the development, production, and distribution of specialty preparations. The portfolio includes, for example, medications for pain and inflammation, as well as preparations for the treatment of Parkinson's and Alzheimer's diseases. Another important aspect in the field of specialty preparations is the supply of patients with parenteral nutrition solutions. These are used in both outpatient and inpatient settings to provide care for patients with severe diseases. The second area is supply services. Here, Medios offers a comprehensive range of services to support customers in hospital care and outpatient patient care. An important aspect of this area is the support of hospitals in dealing with delegations. For example, training is offered to educate hospital staff on the management of certain diseases. The third area is clinical study support. Medios AG offers services and products to support customers in clinical studies. The range includes criteria for patient-related logistics, the delivery of placebos and blinded medications, as well as specialty preparations and parenteral nutrition solutions. In each of these areas, Medios brings its high expertise and experience to develop the best possible solutions for customers and patients. Overall, Medios AG has established itself as an important partner for the German healthcare sector. The company pursues a clear strategy focused on the development and production of specialty preparations for the treatment of serious and rare diseases. The company places the highest value on the quality and safety of its products, as well as comprehensive consultation and customer care. Medios has a strong network of partners and suppliers in the healthcare industry and is a respected contact for customers and other market participants due to its experience and expertise. Medios is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medios stock

Rule of 40 of Medios is 12.40 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Medios since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Medios

All Key Metrics — Medios